By Karen Roman
Biotechnology company Medera Inc. said it will start the Cohort B (high-dose) trial of SRD-002, the first-in-human cardiac gene therapy for Heart Failure with Preserved Ejection Fraction.
The company finished Cohort A (low-dose) with favorable efficacy results after six months of dosing, it said in a statement.
“SRD-002 has been well tolerated with no unexpected events or toxicities observed and promising efficacy results observed in some patients in Cohort A,” said Roger Hajjar, MD, Medera’s President and co-founder. “We expect to complete enrolment in the second cohort in the first quarter 2025, with an interim data readout anticipated in the first half of 2025.”
Contact:
Editor@executives-edge.com
